Skip Navigation LinksHome > August 15, 2013 - Volume 63 - Issue 5 > No Clinically Significant Drug-Resistance Mutations in HIV-1...
JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0b013e31829308f8
Brief Report: Basic and Translational Science

No Clinically Significant Drug-Resistance Mutations in HIV-1 Subtype C–Infected Women After Discontinuation of NRTI-Based or PI-Based HAART for PMTCT in Botswana

Souda, Sajini MBBS, MD, DTM&H*,†; Gaseitsiwe, Simani PhD*; Georgette, Nathan; Powis, Kathleen MD, MPH*,§,‖; Moremedi, Daisy B.Bus*; Iketleng, Thato BSc*; Leidner, Jean MS; Moffat, Claire MBChB, MPH*; Ogwu, Anthony MBBS, MPH*; Lockman, Shahin MD, MSc*,‖,¶; Moyo, Sikhulile MPH*; Mmalane, Mompati FRCSEd, MSc*; Musonda, Rosemary PhD*; Makhema, Joseph MBChB, MRCP*; Essex, Max DVM, PhD*,‖; Shapiro, Roger MD, MPH*,‖,#

Collapse Box

Abstract

Abstract: Risk of developing drug resistance after stopping antiretroviral regimens to prevent mother-to-child HIV-1 transmission is unknown. The Mma Bana Study randomized treatment-naive pregnant women with CD4 ≥200 cells per cubic millimeter to receive either abacavir/zidovudine/lamivudine [triple nucleoside reverse transcriptase inhibitor (NRTI) arm] or lopinavir/ritonavir/zidovudine/lamivudine [protease inhibitor (PI) arm]. Drugs were discontinued after 6 months of breastfeeding. One month after discontinuation, 29 NRTI arm samples and 25 PI arm samples were successfully genotyped. No clinically significant antiretroviral resistance mutations were detected. Eight minor resistance mutations were found among 11 (20%) women (3 from NRTI arm and 8 from PI arm), occurring at similar frequencies to those reported in HIV-1 subtype C treatment-naive cohorts.

© 2013 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.